 CAMBRIDGE, Mass., May 26, 2022 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq:RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM for the treatment of cancer and autoimmune diseases, today announced that the Company will present a Trials in Progress poster presentation for its second broad immune stimulation program, RTX-224, at the American Society of Clinical Oncology ASCO Annual Meeting being held virtually from June 3-7, 2022. 